IP Library › Granted Patent US 12,290,599
Granted Patent B2
US 12,290,599 · App. 17/020,567 · Granted May 6, 2025

Oil-based wound care compositions and methods

Inventor: Bradley Burnam (Calabasas, CA)
Assignee: GLOBAL HEALTH SOLUTIONS LLC
A61K9/10A61K8/00A61K8/044A61K8/31A61K9/0014A61K9/06A61K31/785A61K38/1825A61K38/1841A61K38/20A61K45/06A61K47/06A61Q19/00A61K2800/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,599
App. No.
17/020,567
Granted
May 6, 2025
Kind
B2
Abstract

Compositions and methods for wound care or the dressing or treatment of wounds in a subject in need thereof. The compositions include an oil-based carrier, a polar solvent comprising one or more polar antimicrobial agents, and collagen or a collagen-based material. In at least some instances, the polar solvent comprising the one or more polar antimicrobial agents and the collagen or collagen-based material are suspended in the oil-based carrier.

Claims (34)

1. An oil-based composition for the treatment or dressing of a wound, the composition comprising:

an oil-based carrier;

a polar solvent comprising one or more polar antimicrobial agents, wherein the polar solvent comprising one or more polar antimicrobial agents is suspended in the oil-based carrier; and

powdered collagen or a powdered collagen-based material, wherein the powdered collagen or powdered collagen-based material is suspended in the oil-based carrier,

wherein the oil-based carrier comprises petrolatum, the petrolatum comprising greater than about 60% by weight of the oil-based composition;

wherein the polar solvent is selected from the group consisting of water, ethanol, a mixture of water and ethanol, ascetic acid, and any combination thereof; and

wherein the powdered collagen or powdered collagen-based material comprises from about 5 wt % to about 35 wt % of the oil-based composition.

2. The composition according to claim 1 , wherein the polar solvent comprising one or more antimicrobial agents and/or the powdered collagen or powdered collagen-based material does not separate from the oil-based carrier for at least 6 months.

3. The composition according to claim 1 , wherein the powdered collagen or powdered collagen-based material is characterized by an average particle size of from about 5 microns to about 80 microns.

4. The composition according to claim 1 , where in the powdered collagen or powdered collagen-based material comprises a material selected from the group consisting of extracellular matrix materials, micronized extracellular matrix, purified collagen, Type I collagen, Type II collagen, Type III collagen, Type X collagen, collagen fibers, collagen fibrils, micronized collagen, defibrillated collagen, coarse collagen bundles, non-crosslinked collagen, non-mineralized collage, collagen treated to control cross-linking, collagen-glycosaminoglycan (GAG) mixtures, and any combination thereof.

5. The composition according to claim 1 , wherein the oil-based carrier further comprises one or more selected from the group consisting of animal oil, vegetable oil, natural oil, synthetic oil, hydrocarbon oils, silicone oils, and semi-synthetic derivatives thereof, and any combination thereof.

6. The composition according to claim 1 , wherein the oil-based carrier further comprises one or more selected from the group consisting of mineral oil, squalene oil, flavor oils, silicon oil, essential oils, water insoluble vitamins, Isopropyl stearate, Butyl stearate, Octyl palmitate, Cetyl palmitate, Tridecyl behenate, Diisopropyl adipate, Dioctyl sebacate, Menthyl anthranhilate, Cetyl octanoate, Octyl salicylate, Isopropyl myristate, neopentyl glycol dicarpate cetols, Decyl oleate, diisopropyl adipate, C12-15 alkyl lactates, Cetyl lactate, Lauryl lactate, Isostearyl neopentanoate, Myristyl lactate, Isocetyl stearoyl stearate, Octyldodecyl stearoyl stearate, Hydrocarbon oils, Isoparaffin, Fluid paraffins, Isododecane, Argan oil, Canola oil, Chile oil, Coconut oil, corn oil, Cottonseed oil, Flaxseed oil, Grape seed oil, Mustard oil, Olive oil, Palm oil, Palm kernel oil, Peanut oil, Pine seed oil, Poppy seed oil, Pumpkin seed oil, Rice bran oil, Safflower oil, Tea oil, Truffle oil, Vegetable oil, Apricot (kernel) oil, Jojoba oil ( Simmondsia chinensis seed oil), Grapeseed oil, Macadamia oil, Wheat germ oil, Almond oil, Rapeseed oil, Gourd oil, Soybean oil, Sesame oil, Hazelnut oil, Maize oil, Sunflower oil, Hemp oil, Bois oil, Kuki nut oil, Avocado oil, Walnut oil, Fish oil, berry oil, allspice oil, juniper oil, seed oil, almond seed oil, anise seed oil, celery seed oil, cumin seed oil, nutmeg seed oil, leaf oil, basil leaf oil, bay leaf oil, cinnamon leaf oil, common sage leaf oil, eucalyptus leaf oil, lemon grass leaf oil, melaleuca leaf oil, oregano leaf oil, patchouli leaf oil, peppermint leaf oil, pine needle oil, rosemary leaf oil, spearmint leaf oil, tea tree leaf oil, thyme leaf oil, wintergreen leaf oil, flower oil, chamomile oil, clary sage oil, clove oil, geranium flower oil, hyssop flower oil, jasmine flower oil, lavender flower oil, manuka flower oil, Marhoram flower oil, orange flower oil, rose flower oil, ylang-ylang flower oil, Bark oil, cassia Bark oil, cinnamon bark oil, sassafras Bark oil, camphor wood oil, cedar wood oil, rosewood oil, sandalwood oil, rhizome (ginger) wood oil, resin oil, frankincense oil, myrrh oil, peel oil, bergamot peel oil, grapefruit peel oil, lemon peel oil, lime peel oil, orange peel oil, tangerine peel oil, root oil, valerian oil, Oleic acid, Linoleic acid, Oleyl alcohol, Isostearyl alcohol, semi-synthetic derivatives thereof, and any combination thereof.

7. The composition according to claim 1 , wherein the oil-based based carrier further comprises coconut oil.

8. The composition according to claim 1 , wherein the composition comprises greater than about 80% by weight petrolatum.

9. The composition according to claim 1 , wherein the one or more polar antimicrobial agents comprises polyhexamethylene biguanide (PHMB).

10. The composition according to claim 9 , wherein the composition comprises from about 0.05% to about 5% by weight PHMB.

11. The composition according to any to claim 1 , wherein the one or more polar antimicrobial agents comprises a cationic biocide.

12. The composition according to claim 11 , wherein the cationic biocide is selected from the group consisting of benzalkonium chloride, cetrimide, chlorhexidine, polihexanide biguanide, and salts or combinations thereof.

13. The composition according to claim 1 , wherein the polar solvent further comprises a preservative selected from the group consisting of benzalkonium chloride, cetrimide, chlorhexidine, and any combination thereof.

14. The composition according to claim 1 , wherein the composition comprises from about 0.001% to about 0.15% by weight benzalkonium chloride (BZK).

15. The composition according to claim 1 , wherein the composition excludes an added emulsifier other than the recited components.

16. The composition according to claim 1 , wherein the composition is a topical cream or ointment for application to the wound of a subject in need thereof.

17. The composition according to claim 1 , wherein the composition is prepared by a process comprising:

a) dissolving the one or more polar antimicrobial agents in a polar solvent to give an antimicrobial agent solution;

b) heating the oil-based carrier to a temperature sufficient to cause the oil-based carrier to melt or to a temperature sufficient to provide a oil-based carrier density capable of suspending a powdered collagen or a powdered collagen-based material, resulting in a melted oil-based carrier;

c) mixing a powdered collagen or a powdered collagen-based material into the melted oil-based carrier to give a suspended collagen oil-based carrier composition;

d) heating the antimicrobial agent solution to a temperature higher than the temperature of the melted oil-based carrier to give a heated antimicrobial solution;

e) mixing the suspended collagen oil-based carrier composition and the heated antimicrobial solution to give a melted mixture; and

f) cooling the melted mixture to give the oil-based composition.

18. The composition according to claim 17 , wherein the heated antimicrobial solution has a temperature that is about 1° C. to about 5° C. higher than the temperature of the suspended collagen oil-based carrier composition at the time of mixing.

19. A method of treating or dressing a wound or a post-surgical skin graft in a subject, the method comprising applying the composition according to claim 1 to a wound or post-surgical skin graft in need of dressing or treatment.

20. The method according to claim 19 , further comprising:

contacting the composition according to claim 1 to a wound covering, wherein the wound covering is a selected from the group consisting of a bandage, wrap, gauze, sponge, and film; and

applying the wound covering to the wound or post-surgical skin graft in need of treatment.

Continuity (7)
Continuation In Part 16917846 · Jun 30, 2020
Continuation 15167099 · May 27, 2016
Provisional Application 62182034 · Jun 19, 2015
Provisional Application 62319449 · Apr 7, 2016
Provisional Application 62326150 · Apr 22, 2016
Provisional Application 62338995 · May 19, 2016
Related Publication 20200405637A1 · Dec 31, 2020
References Cited (72)
US 2640801A · Burkhart et al. · 1953 [cited by applicant]
US 4895452A · Yiournas et al. · 1990 [cited by applicant]
US 5466463A · Ford · 1995 [cited by applicant]
US 5994300A · Bayne et al. · 1999 [cited by applicant]
US 6106855A · Haynes et al. · 2000 [cited by applicant]
US 6248338B1 · Müller et al. · 2001 [cited by applicant]
US 6309664B1 · Mathur et al. · 2001 [cited by applicant]
US 7074459B2 · Stockel · 2006 [cited by applicant]
US 7365200B2 · Sircar et al. · 2008 [cited by applicant]
US 8323674B2 · Antoni-Zimmermann et al. · 2012 [cited by applicant]
US 10675243B2 · Burnam · 2020 [cited by applicant]
US 10722461B2 · Burnam · 2020 [cited by applicant]
US 10874608B2 · Burnam · 2020 [cited by applicant]
US 10966927B2 · Burnam · 2021 [cited by applicant]
US 11565020B2 · Burnam · 2023 [cited by applicant]
US 20020146440A1 · Smith · 2002 [cited by applicant]
US 20030012741A1 · Furlan et al. · 2003 [cited by applicant]
US 20050019431A1 · Modak et al. · 2005 [cited by applicant]
US 20050048020A1 · Willie · 2005 [cited by applicant]
US 20060051385A1 · Scholz · 2006 [cited by applicant]
US 20070020213A1 · Tamarkin · 2007 [cited by examiner]
US 20070048345A1 · Huang et al. · 2007 [cited by applicant]
US 20070141091A1 · Xia et al. · 2007 [cited by applicant]
US 20080279944A1 · Sawhney · 2008 [cited by applicant]
US 20080287336A1 · Patel et al. · 2008 [cited by applicant]
US 20090136435A1 · Mulvanerty · 2009 [cited by applicant]
US 20090162304A1 · DiLeva · 2009 [cited by applicant]
US 20090269394A1 · Baker, Jr. et al. · 2009 [cited by applicant]
US 20090281013A1 · Patel et al. · 2009 [cited by applicant]
US 20100092526A1 · Baker, Jr. et al. · 2010 [cited by applicant]
US 20100203139A1 · Baker, Jr. et al. · 2010 [cited by applicant]
US 20100226983A1 · Sutcliffe et al. · 2010 [cited by applicant]
US 20100233224A1 · Ramadurai et al. · 2010 [cited by applicant]
US 20110002820A1 · Dawson et al. · 2011 [cited by applicant]
US 20110052656A1 · Whitekettle et al. · 2011 [cited by applicant]
US 20110251285A1 · Tien et al. · 2011 [cited by applicant]
US 20130011342A1 · Tamarkin · 2013 [cited by examiner]
US 20130150765A1 · Moghe et al. · 2013 [cited by applicant]
US 20140234419A1 · McAnulty et al. · 2014 [cited by applicant]
US 20140248219A1 · Tamarkin et al. · 2014 [cited by applicant]
US 20140276493A1 · Leung · 2014 [cited by examiner]
US 20160106674A1 · Scalesciani · 2016 [cited by applicant]
US 20160206567A1 · Ridden et al. · 2016 [cited by applicant]
US 20160367504A1 · Burnam · 2016 [cited by applicant]
US 20160367676A1 · Burnam · 2016 [cited by applicant]
US 20170232004A1 · Genberg et al. · 2017 [cited by applicant]
US 20170333346A1 · Burnam · 2017 [cited by applicant]
US 20170354754A1 · Liden et al. · 2017 [cited by applicant]
US 20180008711A1 · Selner · 2018 [cited by applicant]
US 20180036236A1 · Selner · 2018 [cited by applicant]
US 20190015548A1 · Harrell · 2019 [cited by applicant]
US 20200268660A1 · Burnam · 2020 [cited by applicant]
US 20200330381A1 · Burnam · 2020 [cited by applicant]
US 20200397869A1 · Leung et al. · 2020 [cited by applicant]
US 20200405637A1 · Burnam · 2020 [cited by applicant]
US 20210186874A1 · Burnam · 2021 [cited by applicant]
US 20220249734A1 · Burnam · 2022 [cited by applicant]
CN 1771937A · 2006 [cited by applicant]
CN 103182070A · 2013 [cited by applicant]
EP 1872788A1 · 2008 [cited by applicant]
WO WO2005053617 · 2005 [cited by examiner]
WO 2006099359A2 · 2006 [cited by applicant]
WO WO2013183770 · 2013 [cited by examiner]
WO 2013186766A1 · 2013 [cited by applicant]
WO 2014183770A1 · 2014 [cited by applicant]
WO 2015118069A1 · 2015 [cited by applicant]
WO 2016126982A1 · 2016 [cited by applicant]
WO 2018226479A1 · 2018 [cited by applicant]
European Search Report; European Application No. 16812129.1; mailed Feb. 22, 2019. [cited by applicant]
Supplementary European Search Report; European Application No. 16812128.3; mailed Mar. 12, 2019. [cited by applicant]
Hwang, Chiaw-Chi et al., Percutaneous Absorption of Flufenamic Acid in Rabbits; Effect of Dimethyl Sulfoxide and Various Nonionic Surface-Active Agents; Journal of Pharmaceutical Association, U.S., vol. 72, No. 8, Aug. … [cited by applicant]
Fuchs, T. et al., “Benzalkoniumchlorid-relevantes Kontaktallergen order Irritans?, Benzalkonium chloride—a relevant contact allergen or irritant?, Results of a multicenter study of the German Contact Allergy Group”I Hau… [cited by applicant]